Bolt Biotherapeutics (BOLT)
(Delayed Data from NSDQ)
$1.11 USD
-0.02 (-1.34%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $1.10 -0.01 (-0.45%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BOLT 1.11 -0.02(-1.34%)
Will BOLT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BOLT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BOLT
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Surpass Estimates
BOLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q1 Loss, Tops Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Misses Revenue Estimates
Biohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy?
Other News for BOLT
Bolt Metals Completes $231K Private Placement
12 Health Care Stocks Moving In Wednesday's After-Market Session
Bolt Biotherapeutics: A Strong Buy on Clinical Progress and Financial Stability
Bolt Biotherapeutics’ Promising Trajectory in Immuno-Oncology: A Strong Buy Recommendation
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Intuitive Surgical (ISRG) and Bolt Biotherapeutics (BOLT)